Finding a trial for a patient means identifying a potentially relevant study and then confirming its current suitability with the research team. A registry entry is not an invitation, a treatment recommendation or proof that a nearby site has an available place. ClinicalTrials.gov and NIHR Be Part of Research are discovery routes, not substitutes for that confirmation.
Start with the question the patient is asking
A fictional patient says they would like to "try a trial" after reading about research online. Before searching, clarify what they hope participation might offer and what kinds of research they would consider.
They may mean access to an experimental treatment, a non-interventional study, an opportunity to contribute samples or a chance to help improve services. Those are different requests. Starting with the word "trial" can narrow the conversation prematurely.
Establish the relevant clinical information through the treating team and appropriate records. Do not create a search profile from an incomplete diagnosis label or assume that a treatment mentioned by the patient describes their confirmed eligibility category.
Use the two routes for discovery
ClinicalTrials.gov is a public study registry. When using a record, inspect the actual study details rather than relying on the search-result title. This article does not report a live shortlist or confirm that any individual trial is recruiting on 19 September 2026.
NIHR Be Part of Research, checked on that date, offers a study-search route and directs questions about suitability to the individual study team. Its central support team explicitly does not determine whether someone is suitable for a particular study.
For a UK patient, NIHR can be a useful local starting point; an international registry can broaden discovery. Neither should be ranked by the raw number of search results when the practical goal is finding an appropriate, accessible opportunity.
Read eligibility as a set of conditions
Suppose the fictional patient finds a record mentioning their condition. The title looks relevant, but eligibility may depend on disease characteristics, previous treatment, current health, investigations or other factors that a broad search does not capture.
Do not compress that detail into "you qualify". Instead, identify the conditions that appear relevant, which are already known and which need clarification. The study team may need information that the patient or referring clinician cannot determine from the public summary alone.
The US National Cancer Institute's trial-search guidance, checked on 19 September 2026, similarly treats finding a study and discussing eligibility with the research team as separate steps. Its examples are cancer-specific, but the distinction illustrates a general search discipline without establishing rules for every specialty.
A potentially relevant study is a reason to enquire, not a conclusion about enrolment.
Check location and status together
A study may list several sites. The practical question is whether the relevant site is recruiting the relevant group now, not whether the study has ever recruited somewhere.
Record the study identifier, the site of interest, the public status and the date you checked it. Then confirm current availability using the listed contact route. A record can be accurate as a study description while still being insufficient to plan travel or alter care.
Ask about the practical commitments as well as eligibility: visits, tests, duration, possible remote activity and the process for discussing participation. Do not assume that a study labelled remote removes every in-person requirement.
Avoid advising the patient to postpone indicated care while waiting for an unconfirmed research opportunity. Decisions about ongoing treatment belong with the responsible clinical team, informed by what the study team can actually offer.
A useful first enquiry
An original enquiry might say: "We are seeking information about study [identifier] at your site. The patient has the relevant confirmed diagnosis and is interested in learning about participation. Could you confirm current recruitment, the appropriate referral process and which clinical details are required for an eligibility discussion?"
Complete the identifier and clinical statements only from verified information. Share patient-specific material through the approved route, with the necessary permissions, rather than attaching a full record to an informal message because it seems convenient.
The enquiry should make the next step easy. A long narrative without the study identifier, site or question may delay clarification. Equally, an excessively brief message can omit the information needed to direct it appropriately.
Discuss research without promising benefit
A patient may interpret eligibility as evidence that the experimental intervention is likely to help them. Explain that research is designed to answer questions and may involve uncertainty, comparisons, additional procedures or burdens that need discussion with the study team.
Ask what matters to the patient about participation. Travel, time away from work, caring responsibilities and tolerance of additional investigations may be decisive even when the clinical criteria appear suitable.
The clinician does not need to reproduce the entire consent process in a preliminary conversation. The aim is to help the patient reach that process with realistic expectations and an opportunity to ask informed questions.
If a study is unsuitable or unavailable, say what was established and what was not. "No suitable study was found in this search" is more accurate than "there are no studies anywhere".
Keep an enquiry trail, not a false matching score
A simple record can include the study identifier, source, date checked, potential relevance, unresolved eligibility points, site contacted and response. That is an original organisational aid, not a validated matching algorithm.
Do not assign a percentage match from an unstructured clinical summary. It would suggest a precision the search has not earned. Likewise, a polished AI list should not be treated as current recruitment information until the underlying records and contacts have been checked.
This article is published by iatroX and includes its own limited role. iatroX can support understanding of clinical concepts or research terminology; it is not being presented here as an automated trial-matching service. Its reference methodology checked on 19 September 2026 should be understood as a source-based learning design, not a promise of current study eligibility.
Frequently asked questions
Does a recruiting listing mean the patient can enrol?
No: the relevant site must confirm current availability and assess the study's eligibility requirements. A public listing is only the beginning of that process.
Should a patient contact NIHR's general support team to confirm eligibility?
NIHR directs suitability questions to the individual study team. Use the contact details associated with the study and the appropriate clinical route.
Can an AI-generated trial list be used as a final recommendation?
No: verify the study, status, site and eligibility process against current primary information. Do not infer suitability from a generated summary.